Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotinyl alcohol is a small molecule niacin (nicotinic acid) derivative used primarily as a peripheral vasodilator and hypolipidemic agent. It acts by directly dilating blood vessels, leading to increased blood flow and decreased blood pressure, and is used in the treatment of peripheral vascular diseases such as arteriosclerosis obliterans, Raynaud's disease, thromboangiitis obliterans (Buerger's disease), arterial embolism, chilblains, or migraine associated with vascular spasm. Its mechanism of action involves direct vasodilation through relaxation of smooth muscle in the vessel wall. Nicotinyl alcohol also decreases the formation and secretion of very low-density lipoprotein (VLDL) by the liver via inhibition of fatty acid mobilization from adipose tissue[1][2][6][8]. Common side effects include flushing and warmth or redness of the skin[4]. It was developed to provide longer-lasting vasodilatory effects compared to nicotinic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotinyl alcohol.